Sinovac Biotech Ltd (SVA) - Net Assets

Latest as of June 2026: $6.46 Billion USD

Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has net assets worth $6.46 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.14 Billion) and total liabilities ($1.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SVA strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets $6.46 Billion
% of Total Assets 79.43%
Annual Growth Rate 57.73%
5-Year Change -53.86%
10-Year Change 4837.41%
Growth Volatility 2243.55

Sinovac Biotech Ltd - Net Assets Trend (1998–2025)

This chart illustrates how Sinovac Biotech Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Sinovac Biotech Ltd market cap and net worth.

Annual Net Assets for Sinovac Biotech Ltd (1998–2025)

The table below shows the annual net assets of Sinovac Biotech Ltd from 1998 to 2025. Also explore Sinovac Biotech Ltd (SVA) equity growth momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 $6.40 Billion -37.80%
2024-12-31 $10.29 Billion -14.38%
2023-12-31 $12.02 Billion -5.43%
2022-12-31 $12.71 Billion -8.38%
2021-12-31 $13.88 Billion +1138.79%
2020-12-31 $1.12 Billion +218.04%
2019-12-31 $352.19 Million +20.64%
2018-12-31 $291.93 Million +125.14%
2017-12-31 $129.67 Million 0.00%
2016-12-31 $129.67 Million -5.01%
2015-12-31 $136.50 Million -3.68%
2014-12-31 $141.73 Million -1.33%
2013-12-31 $143.64 Million +10.97%
2012-12-31 $129.44 Million -10.92%
2011-12-31 $145.30 Million -1.66%
2010-12-31 $147.76 Million +74.93%
2009-12-31 $84.47 Million +57.48%
2008-12-31 $53.64 Million +63.02%
2007-12-31 $32.90 Million +54.41%
2006-12-31 $21.31 Million +29.07%
2005-12-31 $16.51 Million +6.08%
2004-12-31 $15.56 Million +42.94%
2003-12-31 $10.89 Million +10848.47%
2002-12-31 $99.44K +114.56%
2001-12-31 $-682.96K 0.00%
2000-12-31 $-682.96K -2454.45%
1998-12-31 $29.01K --

Equity Component Analysis

This analysis shows how different components contribute to Sinovac Biotech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 281594849300.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings $2.82 Billion 63.44%
Common Stock $72.00K 0.00%
Other Comprehensive Income $1.07 Billion 24.17%
Other Components $550.17 Million 12.39%
Total Equity $4.44 Billion 100.00%

Sinovac Biotech Ltd Competitors by Market Cap

The table below lists competitors of Sinovac Biotech Ltd ranked by their market capitalization.

Company Market Cap
Nanjing Quanxin Cable Technology Co Ltd
SHE:300447
 $642.55 Million
Guangdong Insight Brand Marketing Group Co Ltd
SHE:300781
 $642.64 Million
Baotou Huazi Industry Co Ltd
SHG:600191
 $642.90 Million
Papa John's International Inc
NASDAQ:PZZA
 $643.62 Million
New York Mortgage Trust Inc
NASDAQ:NYMT
 $642.13 Million
Basellandschaftliche Kantonalbank
SW:BLKB
 $642.12 Million
Xinjiang Yilite Industry Co Ltd
SHG:600197
 $641.86 Million
Mingchen Health Co Ltd Class A
SHE:002919
 $641.80 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sinovac Biotech Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 8,262,258,000 to 4,438,943,000, a change of -3,823,315,000 (-46.3%).
  • Net loss of 59,680,000 reduced equity.
  • Dividend payments of 3,513,490,000 reduced retained earnings.
  • Other comprehensive income increased equity by 1,072,761,000.
  • Other factors decreased equity by 1,322,906,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-59.68 Million -1.34%
Dividends Paid $3.51 Billion -79.15%
Other Comprehensive Income $1.07 Billion +24.17%
Other Changes $-1.32 Billion -29.8%
Total Change $- -46.27%

Book Value vs Market Value Analysis

This analysis compares Sinovac Biotech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.10x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1315.99x to 0.10x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1998-12-31 $0.00 $6.47 x
2000-12-31 $-0.10 $6.47 x
2001-12-31 $-0.10 $6.47 x
2002-12-31 $0.01 $6.47 x
2003-12-31 $0.17 $6.47 x
2004-12-31 $0.38 $6.47 x
2005-12-31 $0.50 $6.47 x
2006-12-31 $0.50 $6.47 x
2007-12-31 $0.74 $6.47 x
2008-12-31 $1.13 $6.47 x
2009-12-31 $1.64 $6.47 x
2010-12-31 $2.38 $6.47 x
2011-12-31 $2.38 $6.47 x
2012-12-31 $2.14 $6.47 x
2013-12-31 $2.31 $6.47 x
2014-12-31 $2.27 $6.47 x
2015-12-31 $2.16 $6.47 x
2016-12-31 $2.28 $6.47 x
2017-12-31 $2.28 $6.47 x
2018-12-31 $3.90 $6.47 x
2019-12-31 $2.68 $6.47 x
2020-12-31 $6.57 $6.47 x
2021-12-31 $81.82 $6.47 x
2022-12-31 $78.14 $6.47 x
2023-12-31 $87.44 $6.47 x
2024-12-31 $114.98 $6.47 x
2025-12-31 $61.77 $6.47 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sinovac Biotech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -1.34%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -15.46%
  • • Asset Turnover: 0.04x
  • • Equity Multiplier: 1.95x
  • Recent ROE (-1.34%) is above the historical average (-2.85%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1998 -22.38% 0.00% 0.00x 1.16x $-9.39K
2000 0.00% -150.93% 1.18x 0.00x $-412.39K
2001 0.00% -152.15% 1.18x 0.00x $-416.30K
2002 -175.19% -33.55% 2.20x 2.38x $-184.15K
2003 -14.18% -30.73% 0.19x 2.42x $-1.49 Million
2004 -37.52% -72.31% 0.29x 1.80x $-5.91 Million
2005 -26.62% -68.08% 0.28x 1.42x $-6.04 Million
2006 -3.62% -4.53% 0.41x 1.92x $-2.62 Million
2007 25.50% 22.81% 0.58x 1.91x $4.65 Million
2008 16.74% 17.23% 0.60x 1.62x $3.23 Million
2009 28.25% 23.70% 0.58x 2.06x $12.89 Million
2010 -6.73% -25.47% 0.16x 1.70x $-21.15 Million
2011 -0.65% -1.48% 0.26x 1.66x $-13.84 Million
2012 -12.62% -30.18% 0.24x 1.77x $-26.63 Million
2013 5.78% 10.37% 0.30x 1.87x $-5.43 Million
2014 -1.20% -2.41% 0.26x 1.88x $-14.17 Million
2015 -1.16% -2.10% 0.33x 1.67x $-13.58 Million
2016 -0.46% -0.82% 0.34x 1.63x $-13.56 Million
2017 19.90% 14.80% 0.82x 1.63x $12.84 Million
2018 8.59% 9.48% 0.62x 1.46x $-3.56 Million
2019 15.28% 18.26% 0.54x 1.54x $15.53 Million
2020 14.79% 21.61% 0.27x 2.55x $35.72 Million
2021 90.78% 43.70% 1.16x 1.80x $7.53 Billion
2022 1.28% 7.63% 0.11x 1.58x $-778.28 Million
2023 -1.15% -22.29% 0.03x 1.57x $-970.86 Million
2024 1.10% 25.16% 0.03x 1.49x $-735.32 Million
2025 -1.34% -15.46% 0.04x 1.95x $-503.57 Million

Industry Comparison

This section compares Sinovac Biotech Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $155,284,061
  • Average return on equity (ROE) among peers: -25.94%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sinovac Biotech Ltd (SVA) $6.46 Billion -22.38% 0.26x $642.44 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $110.17 Million
Abcellera Biologics Inc (ABCL) $966.90 Million -15.14% 0.40x $3.53 Billion
Abeona Therapeutics Inc (ABEO) $9.08 Million -66.39% 1.81x $308.79 Million
Acumen Pharmaceuticals Inc (ABOS) $181.82 Million -56.28% 0.31x $155.29 Million
Abpro Holdings, Inc. (ABP) $-85.14 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $67.00 Million -21.42% 0.32x $1.41 Billion
Arbutus Biopharma Corp (ABUS) $35.44 Million -26.32% 0.18x $960.81 Million
ABVC Biopharma Inc (ABVC) $-124.82K 0.00% 0.00x $28.25 Million
Abivax SA American Depositary Shares (ABVX) $455.01 Million -73.87% 0.28x $7.95 Billion
ACADIA Pharmaceuticals Inc (ACAD) $-22.51 Million 0.00% 0.00x $3.56 Billion

About Sinovac Biotech Ltd

NASDAQ:SVA USA Biotechnology
Market Cap
$642.44 Million
Market Cap Rank
#11077 Global
#2857 in USA
Share Price
$6.47
Change (1 day)
+0.00%
52-Week Range
$6.47 - $6.47
All Time High
$6.47
Categories
Companies in USA Biotechnology
About

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more